請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/3905
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 簡盟月(Meng-Yueh Chien) | |
dc.contributor.author | Ling-Wei Chen | en |
dc.contributor.author | 陳玲崴 | zh_TW |
dc.date.accessioned | 2021-05-13T08:38:19Z | - |
dc.date.available | 2017-03-01 | |
dc.date.available | 2021-05-13T08:38:19Z | - |
dc.date.copyright | 2017-03-01 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-11-21 | |
dc.identifier.citation | 參考文獻
1. Lai YC, Potoka KC, Champion HC, et al. Pulmonary arterial hypertension: the clinical syndrome. Circulation. 2014;115:115-30. 2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015:317. 3. Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60-72. 4. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537. 5. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:34-41. 6. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719-25. 7. Lowe B, Grafe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66:831-6. 8. Halank M, Einsle F, Lehman S, et al. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung. 2013;191:337-43. 9. Pugh ME, Buchowski MS, Robbins IM, et al. Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest. 2012;142:1391-8. 10. Becker-Grunig T, Klose H, Ehlken N, et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;168:375-81. 11. Fox BD, Kassirer M, Weiss I, et al. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. J Card Fail. 2011;17:196-200. 12. Chan L, Chin LM, Kennedy M, et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest. 2013;143:333-43. 13. Weinstein AA, Chin LM, Keyser RE, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Res Med. 2013;107:778-84. 14. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114:1482-9. 15. Zafrir B. Exercise training and rehabilitation in pulmonary arterial hypertension: rationale and current data evaluation. J Cardiopulm Rehabil Prev. 2013;33:263-73. 16. Yuan P, Yuan XT, Sun XY, et al. Exercise training for pulmonary hypertension: a systematic review and meta-analysis. Int J Cardiol. 2015;178:142-6. 17. Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol. 1991;18:1738-44. 18. Saggar R, Sitbon O. Hemodynamics in pulmonary arterial hypertension: current and future perspectives. Am J Cardiol. 2012;110:9-15. 19. 蕭淑芳,吳英黛,徐紹勛等人。原發性肺動脈高壓患者運動能力與生活品質相關因素之探討。物理治療。2010;35:8-15。 20. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005;6:92. 21. White J, Hopkins RO, Glissmeyer EW, et al. Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res. 2006;7:55-65. 22. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:42-50. 23. Rich S. Primary pulmonary hypertension: executive summary from the World Symposium-Primary Pulmonary Hypertension 1998. Geneva: World Health Organization. 1998. 24. Cogan JD, Vnencak-Jones CL, Phillips JA, et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med. 2005;7:169-74. 25. Moreira EM, Gall H, Leening MJ, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PloS one. 2015;10:e0130072. 26. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet. Res Med. 2016;4:306-22. 27. Peacock A, Murphy N, McMurray J, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-09. 28. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-30. 29. 中華民國肺動脈高血壓關心協會。取自 http://www.carepah.org.tw。 30. Arena R, Lavie CJ, Milani RV, et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010;29:159-73. 31. Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation. 2014;130:1820-30. 32. RubinL. Primary pulmonary hypertension. Chest.1993;104:236-50. 33. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest Med. 2013;34:639-50. 34. Magliano M, Isenberg D, Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheumatol. 2002;46:1997-2009. 35. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Patho. 2007;38:893-902. 36. Johnson S, Granton J. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev. 2011;20:277-86. 37. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31:479-88. 38. Chung SM, Lee CK, Lee EY, et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol. 2006;25:866-72. 39. Sung YK, Chung L. Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Rheum Dis Clin North Am. 2015;41:295-313. 40. Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198-204. 41. D'Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012;21:328-37. 42. Adatia I, Kothari SS, Feinstein JA. Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. Chest. 2010;137:52-61. 43. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35-62. 44. Rich S, Dantzker DR, Ayres RE, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-23. 45. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma‐related pulmonary hypertension. Arthritis Rheumatol. 2006;54:3043-50. 46. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8:413-25. 47. Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000prime. 2015;7:06. 48. Chemla D, Castelain V, Herve P, et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002;20:1314-31. 49. Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J. 2008;32:393-398. 50. Bogaard HJ, Abe K, Noordegraaf AV, et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135:794-804. 51. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308-12. 52. Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014;23:476-87. 53. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250-57. 54. Zafrir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. Int J Cardiovasc Imaging. 2007;23:209-15. 55. Badano LP, Ginghina C, Easaw J, et al. Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects. Eur Heart J Cardiovas Imaging. 2010;11:27-37. 56. Benza R, Biederman R, Murali S, et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;52:1683-92. 57. Matthay RA, Shub C. Imaging techniques for assessing pulmonary artery hypertension and right ventricular performance with special reference to COPD. J Thorac Imaging. 1990;5:47-67. 58. Sun XG, Hansen JE, Oudiz RJ, et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104:429-35. 59. Liao L, Smith WT, Tuttle RH, et al. Prediction of death and nonfatal myocardial infarction in high-risk patients: a comparison between the Duke treadmill score, peak exercise radionuclide angiography, and SPECT perfusion imaging. J Nucl Med. 2005;46:5-11. 60. Foster C, Gaeckle T, Braastad R, et al. First-pass radionuclide angiography during bicycle and treadmill exercise. J Nucl Cardiol. 1995;2:485-90. 61. Bayram M, Yancy CW. Transthoracic impedance cardiography: a noninvasive method of hemodynamic assessment. Heart Fail Clin. 2009;5:161-68. 62. Tonelli AR, Alnuaimat H, Li N, et al. Value of impedance cardiography in patients studied for pulmonary hypertension. Lung. 2011;189:369-75. 63. Waxman AB. Exercise physiology and pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55:172-9. 64. Fowler RM, Gain KR, Gabbay E. Exercise intolerance in pulmonary arterial hypertension. Pulm Med. 2012;2012:359204. 65. Desai SA, Channick RN. Exercise in patients with pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2008;28:12-16. 66. Arena R. Exercise testing and training in chronic lung disease and pulmonary arterial hypertension. Prog Cardiovasc Dis. 2011;53:454-63. 67. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123:344-50. 68. Chandra S, Shah SJ, Thenappan T, et al. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010;29:181-87. 69. Blom-Bülow B, Jonson B, Brauer K. Factors limiting exercise performance in progressive systemic sclerosis. Semin Arthritis Rheum. 1983;13:174-81. 70. Sudduth CD, Strange C, Cook WR, et al. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 1993;95:413-8. 71. Tench C, Bentley D, Vleck V, et al. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol. 2002;29:474-81. 72. Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J. 2012;40:1410-9. 73. Groepenhoff H, Vonk-Noordegraaf A, Boonstra A, et al. Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc. 2008;40:1725-32. 74. Triantafyllidi H, Kontsas K, Trivilou P, et al. The importance of cardiopulmonary exercise testing in the diagnosis, prognosis and monitoring of patients with pulmonary arterial hypertension. Hellenic J Cardiol. 2010;51:245-9. 75. Demir R, Küçükoğlu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol. 2015;15:249-54. 76. Rasekaba T, Lee AL, Naughton MT, et al. The six-minute walk test: a useful metric for the cardiopulmonary patient. Int Med J. 2009;39:495-501. 77. Tokgozoglu L, Akdogan A, Okutucu S, et al. Two years of multidisciplinary diagnostic and therapeutic experience in patients with pulmonary arterial hypertension. Turk Kardiyol Dern Ars. 2009;37:378-83. 78. Matura LA, McDonough A, Hanlon AL, et al. Sleep disturbance, symptoms, psychological distress, and health-related quality of life in pulmonary arterial hypertension. Eur J Cardiovasc Nurs. 2015 ;14:423-30. 79. Kyle UG, Genton L, Karsegard L, et a;. Single prediction equation for bioelectrical impedance analysis in adults aged 20-94 years. Nutrition. 2001;17:248-53. 80. Mainguy V, Malenfant S, Neyron AS, et al. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J. 2013;42:425-34. 81. Schmidt C, Theilmeier G, Van Aken H, et al. Comparison of electrical velocimetry and transoesophageal Doppler echocardiography for measuring stroke volume and cardiac output. Br J Anaesth. 2005;95:603-10. 82. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7. 83. Gibbons WJ, Fruchter N, Sloan S, et al. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil Prev. 2001;21:87-93. 84. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83. 85. 曾旭民,盧瑞芬,蔡益堅。國人生活品質評量 (Ⅱ):SF-36 台灣版的常模與效度檢測。臺灣公共衛生雜誌。2003;2:512-18。 86. Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol. 1985;121:91-106. 87. Sallis JF, Buono MJ, Roby JJ, Micale FG, Nelson JA. Seven-day recall and other physical activity self-reports in children and adolescents. Med Sci Sports Exerc. 1993;25:99-108. 88. Taylor CB, Coffey T, Berra K, et al. Seven-day activity and self-report compared to a direct measure of physical activity. Am J Epidemiol. 1984;120:818-24. 89. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-3. 90. Ferentinos P, Kontaxakis VP, Havaki-Kontaxaki BJ, et al. Fatigue in female patients with major depression: the effect of comorbid anxiety disorders. Psychiatrike. 2011;22:320-9. 91. Negura D, Micheletti A, Chessa M, et al. Cardiopulmonary exercise test in adults with congenital heart disease. Pediatr Med Chir. 2010;32:256-9. 92. Riley MS, Pórszász J, Engelen MP, et al. Gas exchange responses to continuous incremental cycle ergometry exercise in primary pulmonary hypertension in humans. Eur J Appl Physiol. 2000;83:63-70. 93. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation. 2002;105:54-60. 94. Yasunobu Y, Oudiz RJ, Sun XG, et al. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005;127:1637-46. 95. Kane GC, Sachdev A, Villarraga HR, et al. Impact of age on pulmonary artery systolic pressures at rest and with exercise. Echo Res. 2016;3:53-61. 96. Sietsema KE, Cooper DM, Perloff JK, et al. Control of ventilation during exercise in patients with central venous-to-systemic arterial shunts. J Appl Physiol. 1988;64:234-42. 97. Gibelin P, Aldossari A, Bertora D, et al. New parameters of cardiopulmonary exercise testing in patients with chronic heart failure: Practical applications. Int J Clin Med. 2012;3;1-6. 98. Guazzi M, Adams V, Conraads V, et al. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2012;33:2917-27. 99. Roman A, Barbera JA, Castillo MJ, et al. Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2013;49:181-8. 100. Kukkonen M, Puhakka A, Halme M. Quality of life among pulmonary hypertension patients in Finland. Eur Clin Respir J. 2016;3:26405. 101. Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with pulmonary arterial hypertension. Pharm Eco . 2016;34:751-70. 102. Torres DF, Zin WA, Lopes AJ, et al. Association between hemodynamic profile, physical capacity and quality of life in pulmonary hypertension. Arq Bras Cardiol. 2015;104:387-93. 103. Miyamoto S, Nagaya N, Sstoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-92 104. Deboeck G, Niset G, Vachiery JL, et al. Physiological response to the six-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2005;26:667-72. 105. Chua R, Keogh A, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Int Med J. 2006;36:705-10. 106. Matura LA, Shou H, Fritz JS, et al. Physical Activity and Symptoms in Pulmonary Arterial Hypertension. Chest. 2016;150:46-56. 107. Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29:178-84. 108. Paolillo S, Farina S, Bussotti M, et al. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. Eur J Prev Cardiol. 2012;19:960-71. 109. Ley S, Fink C, Risse F, et al. Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension. Eur Radio. Feb 2013;23:324-31. 110. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med. 1995;333:710-14. 111. McGinnis G, Kliszczewiscz B, Barberio M, et al. Acute hypoxia and exercise-induced blood oxidative stress. Int J Sport Nutr Exerc Metab. 2014;24:684-93. 112. d'Alonzo G, Gianotti L, Pohil R, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987;92:57-62. 113. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardio. 2006;97:123-26. 114. Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol. 2013;167:1193-98. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/3905 | - |
dc.description.abstract | 研究背景與目的:肺動脈高壓是一種會持續惡化的肺部血管性疾病,病程進展快速,致死率極高。目前由於藥物治療發展,已使肺動脈高壓存活率增加,但患者仍存在運動能力及生活品質下降的問題。過去研究顯示原發性及次發性肺動脈高壓病患的病因和預後都不相同,但少有研究探討這兩類患者的運動能力及生活品質差異,因此本研究目的為比較原發性及次發性肺動脈高壓患者的運動能力及生活品質差異,並分析相關因素。研究方法:共13位符合收案條件的肺高壓患者,5位原發性和8位次發性患者。測試項目包括身體組成、運動能力(六分鐘行走測試、心肺運動測試)、血液動力學(非侵入性心輸出量測試儀)、日常身體活動量、疲勞嚴重程度及生活品質(36題簡短生活品質量表)。使用SPSS19.0版本進行資料分析,以Mann-Whiteny U檢定或Chi-squared檢定分析原發性組與次發性組肺動脈高壓各項測試結果的組間差異,並以Spearman's rank correlation檢定運動能力及生活品質的因素與各項測試參數間的相關性,最後再以迴歸分析影響運動能力的主要因素。研究結果:原發性肺動脈高壓與次發性肺動脈高壓的最大攝氧量年齡預測百分比(64.26±7.12 vs 50.23±12.93 %,p<0.05)、二氧化碳換氣當量斜率(33.90±5.84 vs 51.61±20.97,p<0.05)、無氧閾值時潮氣末二氧化碳(PETCO2@AT)(34.88±3.38 vs 27.62±10.97 毫米汞柱,p<0.05)及無氧閾值時二氧化碳換氣當量(VE/VCO2@AT)(33.56±3.08 vs 41.96±4.74 公升/分鐘,p<0.05)兩組相較有顯著差異。原發性組的六分鐘行走測試距離顯著高於次發性組(565.38±29.61 vs 486.26±70.91公尺,p<0.05)。原發性組與次發性組在血液動力學參數雖無顯著差異,但次發性組有較佳的趨勢。迴歸分析顯示影響肺動脈高壓患者運動能力的主要因素為潮氣末二氧化碳分壓。結論:原發性肺動脈高壓患者的運動能力及運動測試參數與次發性患者存在顯著差異。但原發性及次發性族群運動中血液動力學參數的變化,仍需更多的研究。建議未來須分開探討原發性及次發性肺動脈高壓族群的運動能力與運動反應,且須考慮患者是否具有運動時引起心臟右至左分流。 | zh_TW |
dc.description.abstract | Background and purpose: Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease with high mortality rate. Along with the pharmaceutical development, the prognosis of the disease has improved. However, subsequent poor exercise capacity and decrease of the quality of life still remain as a problem. Previous studies have shown that idiopathic and secondary PH were different in etiology and prognosis, but few studies examined the differences in the exercise capacity and quality of life between these two types of patients. Therefore, the purposes of this study were to compare the exercise capacity and quality of life, and analyzed the factors affecting them in idiopathic and associated PAH. Methods: There were 5 patients diagnosed with idiopathic PAH, and 8 with associated PAH included in the study. Outcome measures included body composition, exercise capacity (six minutes walking test, cardiopulmonary exercise testing), hemodynamics measurements (by non-invasive cardiac output test instrument), regular physical activity, fatigue severity, and quality of life (SF-36). SPSS version 19.0 was used for data analysis. Mann-Whitney U test and X2 were used to analyze between-group differences according to continuous variables or categories. Spearman correlation coefficient was used to test the correlations between the outcome parameters. Multiple linear regression analyses were used to examine the factors associated with maximal oxygen consumption and 6-minute walking distances. Result: There were significant differences between idiopathic and associated PAH in VO2 age pred% (64.26±7.12 vs 50.23±12.93 %, p<0.05)、VE/VCO2 slope (33.90±5.84 vs 51.61±20.97, p<0.05)、VE/VCO2@AT (33.56±3.08 vs 41.96±4.74 l/min, p<0.05)、PETCO2@AT (34.88±3.38 vs 27.62±10.97 mmHg, p<0.05) and 6-minute walking distances (565.38±29.61 vs 486.26±70.91 m, p<0.05). There was no significant in hemodynamics parameters between idiopathic and associated PAH group. The regression model showed the PETCO2@AT was significant associated with exercise capacity. Conclusions: There were significant differences of exercise capacity and cardiopulmonary exercise testing parameters between idiopathic and associated PAH. Future studies should further analyze the differences of characteristics and features between these two groups, and should consider if patient has exercise induce right-left shunt. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T08:38:19Z (GMT). No. of bitstreams: 1 ntu-105-R03428004-1.pdf: 2759688 bytes, checksum: 2310e2d44f26314e445f9fa3a73ca085 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 目錄
口試委員審定書 i 誌謝 ii 中文摘要 iii 英文摘要 v 第一章、前言 1 第一節、研究背景與動機 1 第二節、研究目的 3 第三節、研究假設 4 第四節、研究重要性 5 第二章、文獻回顧 6 第一節、肺高壓簡介 6 第二節、肺動脈高壓的血液動力學評估 11 第三節、原發性及次發性肺動脈高壓之運動能力 13 第四節、原發性與次發性肺動脈高壓之運動測試 14 第五節、原發性與次發性肺動脈高壓對生活品質之影響 15 第三章、研究設計與方法 17 第一節、研究設計與流程 17 第二節、研究對象 17 第三節、評估工具與方法 17 第四節、統計分析 20 第四章、研究結果 21 第一節、受試者基本資料 21 第二節、原發性與次發性肺動脈高壓患者之運動能力與血液動力學參數 21 第三節、原發性與次發性肺動脈高壓患者的健康相關生活品質 22 第四節、影響運動能力與生活品質的相關因素 22 第五章、討論 24 第一節、受試者基本資料 24 第二節、原發性與次發性肺動脈高壓患者的運動能力與血液動力學 24 第三節、原發性與次發性肺動脈高壓患者的健康相關生活品質 27 第四節、影響運動能力與生活品質的相關因素 28 第五節、研究限制 29 第六章、結論 31 參考文獻 32 附錄一、台灣大學醫學院附設醫院倫委會審查通過證明 57 附錄二、36題簡短生活品質量表使用許可 59 附錄三、受試者基本資料表 61 附錄四、七日回憶活動量問卷 63 附錄五、SF-36v2生活品質問卷 65 附錄六、疲勞嚴重程度量表 71 | |
dc.language.iso | zh-TW | |
dc.title | 原發性肺動脈高血壓與次發性肺高壓患者之運動能力與生活品質 | zh_TW |
dc.title | The Exercise Capacity and Quality of Life in the Patients with Idiopathic Pulmonary Arterial Hypertension and Secondary Pulmonary Hypertension | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 徐紹勛(Hsao-Hsun Hsu),陳思遠(Ssu-Yuan Chen),吳彥雯(Yen-Wen Wu) | |
dc.subject.keyword | 肺動脈高壓,心肺運動測試,血液動力學,運動能力,生活品質, | zh_TW |
dc.subject.keyword | Pulmonary arterial hypertension,Cardiopulmonary exercise testing,Hemodynamics measurements,Exercise capacity,Quality of life., | en |
dc.relation.page | 71 | |
dc.identifier.doi | 10.6342/NTU201603751 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2016-11-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 物理治療學研究所 | zh_TW |
顯示於系所單位: | 物理治療學系所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf | 2.7 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。